Australia: Where Value Beats Cost
In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is going through globally: the country deals with patent cliffs, companies are…
Address: Level 3, 235 Pyrmont Street,Pyrmont, NSW 2009
Sydney, Australia
Tel: +61 (0)2 8569 1400
Web: http://www.novotech-cro.com/
Established in 1996, Novotech is the largest independent CRO in Australia. With operations in Australia, New Zealand, the United States, India, and South Korea, Novotech’s service offering has come to be recognized for its quality both by our clients, as well as industry analyst groups. The demand for global clinical outsourcing services continues to grow at a rapid pace, with Asia providing the new frontier. Headquartered in Australia, Novotech is the ideal gateway for expansion of clinical programs into the region.
Novotech’s comprehensive range of services extend the full spectrum of clinical drug development needs. Novotech’s Australian Head Office is situated in Sydney, with regional offices in Melbourne and Brisbane providing easy access to the most important population centres in Australia. Supported by regional staff across the country and in New Zealand, Novotech’s coverage of the Australia/New Zealand region is second to none.
Novotech Sydney is ISO 9001 certified and is regularly audited not only by clients, but external quality endorsement organisations as part of maintaining ISO credentials.
Audits, Medical Writing, Clinical Trials, Biostatistics, Generics, Regulatory Affairs
In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is going through globally: the country deals with patent cliffs, companies are…
Can you outline the significance of the current PBS to the industry and in particular the impact it has on service providers to the industry such as Hahn? As service…
Speaking to the Australian environment, how would you rate the market in terms of companies like Swisse? After traveling the world, the Australian market has shown to be one of…
In our interviews we have been hearing two opinions on the success of PBS reforms: that it works as it should in providing space for innovative medicine listings, and that…
Dr Bernadette Morris-Smith has also participated in this interview TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would you begin…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
“Australia is not just a postbox for selling drugs; Celgene is committed to establishing a major presence in the region,” you said when Focus Reports met you first in 2008.…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
Senior Partner Dr Sree Haran has also participated in this interview. TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would…
The company underwent some landmark changes under your leadership, changing the balance between different pillars of the business – retail, wholesale product delivery, marketing programs. Would you begin by outlining…
After just six months in the country, Novartis Australia’s new Managing Director offers his perspectives on the Australian pharmaceutical market and healthcare system, his company’s commitment to R&D, and…
Can you start by commenting on the state of diabetes in Australia at present? According to 2011 statistics nearly one million Australians have diabetes and about half of those are…
See our Cookie Privacy Policy Here
